Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBITDA: 2014-2024

Historic EBITDA for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to -$273.2 million.

  • Rocket Pharmaceuticals' EBITDA rose 24.74% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 8.51%. This contributed to the annual value of -$273.2 million for FY2024, which is 5.22% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported EBITDA of -$273.2 million as of FY2024, which was down 5.22% from -$259.7 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' EBITDA ranged from a high of -$134.3 million in FY2020 and a low of -$273.2 million during FY2024.
  • In the last 3 years, Rocket Pharmaceuticals' EBITDA had a median value of -$259.7 million in 2023 and averaged -$252.4 million.
  • Data for Rocket Pharmaceuticals' EBITDA shows a maximum YoY plummeted of 76.36% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' EBITDA stood at -$134.3 million in 2020, then fell by 24.53% to -$167.2 million in 2021, then tumbled by 34.14% to -$224.3 million in 2022, then dropped by 15.74% to -$259.7 million in 2023, then dropped by 5.22% to -$273.2 million in 2024.